The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR/ABL in vitro</i> and in a xenograft model of chronic myeloid leukemiaIgnacio García‐Tuñón, Manuel Sánchez‐Martín|Oncotarget|2017Cited by 40
Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiencyIgnacio García‐Tuñón, Manuel Sánchez‐Martín|PLoS ONE|2019Cited by 29